Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007002458) NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/002458 International Application No.: PCT/US2006/024569
Publication Date: 04.01.2007 International Filing Date: 23.06.2006
IPC:
A61K 31/70 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
Applicants:
MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue Rahway, NJ 07065-0907, US (AllExceptUS)
WOLKENBERG, Scott, E. [US/US]; US (UsOnly)
LINDSLEY, Craig, W. [US/US]; US (UsOnly)
ZHAO, Zhijian [US/US]; US (UsOnly)
WILLIAMS, Theresa, M. [US/US]; US (UsOnly)
Inventors:
WOLKENBERG, Scott, E.; US
LINDSLEY, Craig, W.; US
ZHAO, Zhijian; US
WILLIAMS, Theresa, M.; US
Common
Representative:
MERCK & CO., INC.; 126 East Lincoln Avenue Rahway, NJ 07065-0907, US
Priority Data:
60/694,73528.06.2005US
60/707,28311.08.2005US
Title (EN) NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
(FR) INHIBITEURS NON NUCLÉOSIDIQUES DE LA TRANSCRIPTASE INVERSE
Abstract:
(EN) Compounds of Formula (I); are HIV reverse transcriptase inhibitors, wherein R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula (I) and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
(FR) La présente invention concerne des inhibiteurs de la transcriptase inverse du VIH qui sont des composés de Formule (I); dans laquelle R1, R2, R3, R4 et R5 sont définis ici. Les composés de formule (I) et leurs sels pharmaceutiquement acceptables sont utiles pour l'inhibition de la transcriptase inverse du VIH, pour la prophylaxie et le traitement de l'infection par le VIH et pour la prophylaxie, le retard de l'apparition et le traitement du sida. Les composés et leurs sels peuvent être utilisés en tant qu'ingrédients dans des compositions pharmaceutiques, facultativement en combinaison avec d'autres antiviraux, immunomodulateurs, antibiotiques ou vaccins.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP1898928JP2008546839US20100168097CA2612592AU2006261931